Novo Nordisk has become aware of several hundred units of Ozempic® (semaglutide) injection 1 mg distributed outside the Novo ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

About 37% of individuals prescribed semaglutide for obesity achieved 10% or more body weight reduction ... loss at one year was 2% higher for every unit increase in baseline BMI.

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide ... had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...